February 26, 2015
Eisai announced on February 25 that its anticancer agent Halaven (eribulin) statistically significantly prolonged the primary endpoint of overall survival (OS) against dacarbazine in a PIII clinical study in patients with soft tissue sarcomas. Based on the results, the company...read more